Loxo Oncology, Inc. (LOXO) VP Sells $131,250.00 in Stock
Loxo Oncology, Inc. (NASDAQ:LOXO) VP Jennifer Burstein sold 1,500 shares of the company’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $87.50, for a total value of $131,250.00. Following the completion of the transaction, the vice president now directly owns 1,500 shares of the company’s stock, valued at $131,250. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Jennifer Burstein also recently made the following trade(s):
- On Thursday, December 14th, Jennifer Burstein sold 1,700 shares of Loxo Oncology stock. The shares were sold at an average price of $83.27, for a total value of $141,559.00.
- On Monday, November 27th, Jennifer Burstein sold 1,700 shares of Loxo Oncology stock. The shares were sold at an average price of $74.82, for a total value of $127,194.00.
- On Monday, October 30th, Jennifer Burstein sold 1,700 shares of Loxo Oncology stock. The shares were sold at an average price of $87.19, for a total value of $148,223.00.
Shares of Loxo Oncology, Inc. (LOXO) traded up $1.40 during midday trading on Friday, reaching $90.47. The company’s stock had a trading volume of 433,800 shares, compared to its average volume of 319,425. Loxo Oncology, Inc. has a one year low of $36.75 and a one year high of $95.92. The stock has a market capitalization of $2,850.00, a PE ratio of -15.57 and a beta of 2.54.
Loxo Oncology (NASDAQ:LOXO) last issued its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.12) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.38) by $0.26. equities analysts anticipate that Loxo Oncology, Inc. will post -5.91 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently modified their holdings of the business. Quantbot Technologies LP purchased a new stake in Loxo Oncology in the third quarter valued at approximately $122,000. Ameritas Investment Partners Inc. lifted its stake in Loxo Oncology by 31.3% in the second quarter. Ameritas Investment Partners Inc. now owns 1,758 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 419 shares during the last quarter. BNP Paribas Arbitrage SA lifted its stake in Loxo Oncology by 4,388.0% in the second quarter. BNP Paribas Arbitrage SA now owns 2,244 shares of the biopharmaceutical company’s stock valued at $180,000 after buying an additional 2,194 shares during the last quarter. Cambridge Investment Research Advisors Inc. purchased a new stake in Loxo Oncology in the third quarter valued at approximately $212,000. Finally, Amalgamated Bank purchased a new stake in Loxo Oncology in the third quarter valued at approximately $268,000. Institutional investors own 99.98% of the company’s stock.
A number of brokerages recently issued reports on LOXO. BidaskClub raised Loxo Oncology from a “strong sell” rating to a “sell” rating in a report on Tuesday, December 12th. Citigroup lowered their price target on Loxo Oncology from $112.00 to $108.00 and set a “buy” rating for the company in a report on Thursday, November 16th. Morgan Stanley reaffirmed an “overweight” rating and issued a $103.00 price target (up from $95.00) on shares of Loxo Oncology in a report on Friday, October 6th. BTIG Research reaffirmed a “buy” rating and issued a $102.00 price target (up from $75.00) on shares of Loxo Oncology in a report on Friday, September 29th. Finally, JMP Securities raised Loxo Oncology from a “market perform” rating to an “outperform” rating and upped their price target for the company from $77.18 to $95.00 in a report on Tuesday, November 14th. Two investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $90.57.
COPYRIGHT VIOLATION NOTICE: This piece of content was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/loxo-oncology-inc-loxo-vp-sells-131250-00-in-stock/1814000.html.
Loxo Oncology Company Profile
Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.
Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.